cvot tirzepatide SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized Lilly Outdoes Itself, Leqvio Monotherapy,

If you notice the powder looks clumpy or wet, the seal may have been compromised

In laboratory settings, it is widely employed to investigate the mechanisms of growth hormone release and the associated intracellular signaling cascades

According to the World Health Organization, about 60-70% of people in industrialized countries will experience lower back pain at some point in their lives

In people with T2D, a phase 1b study did not demonstrate improvement in HbA1c, however there was a placebo-adjusted WL of 8.5% after 12 weeks (Table 3)

Researchers will track changes in drinking, overall health and quality of life to see whether the drug offers a meaningful alternative

Cardiovasc J Afr